TD Cowen Lowers Myriad Genetics (NASDAQ:MYGN) Price Target to $6.00

Myriad Genetics (NASDAQ:MYGN) had its price target reduced by research analysts at TD Cowen from $7.00 to $6.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a “hold” rating on the stock. TD Cowen’s target price would suggest a potential upside of 45.81% from the company’s current price.

A number of other equities analysts have also recently issued reports on MYGN. UBS Group reduced their price objective on shares of Myriad Genetics from $8.00 to $6.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 24th. Zacks Research upgraded shares of Myriad Genetics from a “strong sell” rating to a “hold” rating in a research report on Thursday, February 26th. Wells Fargo & Company dropped their target price on shares of Myriad Genetics from $6.00 to $5.50 and set an “equal weight” rating for the company in a research report on Wednesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Myriad Genetics in a research note on Friday, March 27th. Four analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Myriad Genetics presently has a consensus rating of “Hold” and an average price target of $8.50.

Myriad Genetics Trading Down 18.2%

Shares of NASDAQ MYGN traded down $0.92 during midday trading on Wednesday, hitting $4.12. The stock had a trading volume of 6,707,510 shares, compared to its average volume of 1,572,915. The company’s 50-day simple moving average is $4.78 and its 200 day simple moving average is $5.90. The firm has a market cap of $388.62 million, a P/E ratio of -1.04 and a beta of 1.81. Myriad Genetics has a fifty-two week low of $3.75 and a fifty-two week high of $8.59. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.49 and a quick ratio of 2.26.

Myriad Genetics (NASDAQ:MYGN) last released its earnings results on Tuesday, May 5th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.03). The firm had revenue of $200.40 million during the quarter, compared to analyst estimates of $202.42 million. Myriad Genetics had a negative net margin of 44.38% and a negative return on equity of 6.35%. The firm’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period last year, the business posted ($0.03) earnings per share. Research analysts anticipate that Myriad Genetics will post -0.37 EPS for the current year.

Insiders Place Their Bets

In related news, Director S. Louise Phanstiel acquired 48,000 shares of the firm’s stock in a transaction that occurred on Friday, February 27th. The stock was acquired at an average cost of $4.66 per share, with a total value of $223,680.00. Following the completion of the purchase, the director directly owned 281,951 shares in the company, valued at approximately $1,313,891.66. This trade represents a 20.52% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Samraat S. Raha acquired 40,000 shares of the firm’s stock in a transaction that occurred on Monday, March 9th. The shares were bought at an average cost of $5.00 per share, with a total value of $200,000.00. Following the completion of the purchase, the chief executive officer owned 493,104 shares of the company’s stock, valued at $2,465,520. This trade represents a 8.83% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have purchased 144,507 shares of company stock valued at $694,548. 1.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Myriad Genetics

Institutional investors have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC grew its stake in Myriad Genetics by 2,333.3% in the second quarter. EverSource Wealth Advisors LLC now owns 4,672 shares of the company’s stock valued at $25,000 after acquiring an additional 4,480 shares during the period. Quarry LP grew its stake in Myriad Genetics by 155.6% in the fourth quarter. Quarry LP now owns 4,365 shares of the company’s stock valued at $27,000 after acquiring an additional 2,657 shares during the period. Hantz Financial Services Inc. grew its stake in Myriad Genetics by 1,088.7% in the third quarter. Hantz Financial Services Inc. now owns 4,089 shares of the company’s stock valued at $30,000 after acquiring an additional 3,745 shares during the period. Royal Bank of Canada grew its stake in Myriad Genetics by 129.6% in the fourth quarter. Royal Bank of Canada now owns 4,993 shares of the company’s stock valued at $31,000 after acquiring an additional 2,818 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in Myriad Genetics in the second quarter valued at about $37,000. 99.02% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Myriad Genetics

Here are the key news stories impacting Myriad Genetics this week:

• Positive Sentiment: Company reiterated FY‑2026 revenue guidance of $860M–$880M and highlighted year‑over‑year test volume growth in its Cancer Care Continuum (+13%) and Mental Health (+7%) segments, which management cites as evidence of ongoing progress in higher‑margin areas. Press Release
• Neutral Sentiment: Wells Fargo lowered its price target from $6.00 to $5.50 and kept an “equal weight” rating — a modest downgrade but still implies upside from current levels, signaling analysts see limited near‑term catalysts but not a more severe downgrade. Benzinga TickerReport
• Neutral Sentiment: Full Q1 earnings call transcript is available for investors who want management’s tone on demand trends, margin drivers and cadence for the rest of the year. Use the call transcript to judge credibility of guidance and segment outlook. Earnings Call Transcript
• Negative Sentiment: Q1 results missed estimates: GAAP loss of $0.09/sh vs. consensus -$0.06 and revenue $200.4M vs. $202.4M expected. The EPS and revenue shortfalls, plus a negative net margin (~44%) and negative ROE, are the primary drivers of today’s selling pressure. Zacks
• Negative Sentiment: Market writeups describe a heavy sell‑off after the Q1 miss; trading volume is well above average, indicating institutional selling and weaker near‑term sentiment. Seeking Alpha

Myriad Genetics Company Profile

Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual’s risk for various hereditary conditions and to guide personalized treatment decisions. The company’s core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women’s health, neurology and pharmacogenomics to support more informed clinical decision-making.

Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities.